Botulinum neurotoxin revisited – An individualised, patient-centric approach for the treatment of dystonia and spasticity

Maja Relja, Jorge Jacinto, Joseph Jankovic, Alberto Albanese

Research output: Contribution to journalArticle

Abstract

Botulinum toxin A (BoNT-A) has become the first-line therapy in cervical dystonia (CD), blepharospasm and spasticity. However, the current guidelines for the clinical use of BoNT-A are based on data published more than 20 years ago and patient satisfaction with current treatment regimens is low. There is a striking difference between the injection intervals given in everyday clinical practice and the injection intervals preferred by patients. Recent data have indicated that shorter injection intervals may improve overall patient satisfaction since re-emergence of symptoms could be prevented. Three double-blind studies have demonstrated that incobotulinumtoxin A (incoBoNT-A) is suitable for use in a flexible, patient-centric approach in blepharospasm and CD, with injection intervals starting from 6 weeks. The efficacy, tolerability and safety of this regime were excellent. There is a need to optimise and individualise the treatment using the three available formulations of BoNT- A, as well as to define parameters for switching between the formulations.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalEuropean Neurological Review
Volume10
Issue number1
Publication statusPublished - Jun 1 2015

Fingerprint

Dystonia
Neurotoxins
Blepharospasm
Torticollis
Type A Botulinum Toxins
Injections
Patient Satisfaction
Therapeutics
Double-Blind Method
Guidelines
Safety

Keywords

  • Blepharospasm
  • Botulinum toxin
  • Cervical dystonia
  • Incobotulinum toxin A
  • Spasticity

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Botulinum neurotoxin revisited – An individualised, patient-centric approach for the treatment of dystonia and spasticity. / Relja, Maja; Jacinto, Jorge; Jankovic, Joseph; Albanese, Alberto.

In: European Neurological Review, Vol. 10, No. 1, 01.06.2015, p. 28-34.

Research output: Contribution to journalArticle

@article{116ec6070deb4b069e2d0e03c7044a7b,
title = "Botulinum neurotoxin revisited – An individualised, patient-centric approach for the treatment of dystonia and spasticity",
abstract = "Botulinum toxin A (BoNT-A) has become the first-line therapy in cervical dystonia (CD), blepharospasm and spasticity. However, the current guidelines for the clinical use of BoNT-A are based on data published more than 20 years ago and patient satisfaction with current treatment regimens is low. There is a striking difference between the injection intervals given in everyday clinical practice and the injection intervals preferred by patients. Recent data have indicated that shorter injection intervals may improve overall patient satisfaction since re-emergence of symptoms could be prevented. Three double-blind studies have demonstrated that incobotulinumtoxin A (incoBoNT-A) is suitable for use in a flexible, patient-centric approach in blepharospasm and CD, with injection intervals starting from 6 weeks. The efficacy, tolerability and safety of this regime were excellent. There is a need to optimise and individualise the treatment using the three available formulations of BoNT- A, as well as to define parameters for switching between the formulations.",
keywords = "Blepharospasm, Botulinum toxin, Cervical dystonia, Incobotulinum toxin A, Spasticity",
author = "Maja Relja and Jorge Jacinto and Joseph Jankovic and Alberto Albanese",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "10",
pages = "28--34",
journal = "European Neurological Review",
issn = "1758-3837",
publisher = "Touch Briefings",
number = "1",

}

TY - JOUR

T1 - Botulinum neurotoxin revisited – An individualised, patient-centric approach for the treatment of dystonia and spasticity

AU - Relja, Maja

AU - Jacinto, Jorge

AU - Jankovic, Joseph

AU - Albanese, Alberto

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Botulinum toxin A (BoNT-A) has become the first-line therapy in cervical dystonia (CD), blepharospasm and spasticity. However, the current guidelines for the clinical use of BoNT-A are based on data published more than 20 years ago and patient satisfaction with current treatment regimens is low. There is a striking difference between the injection intervals given in everyday clinical practice and the injection intervals preferred by patients. Recent data have indicated that shorter injection intervals may improve overall patient satisfaction since re-emergence of symptoms could be prevented. Three double-blind studies have demonstrated that incobotulinumtoxin A (incoBoNT-A) is suitable for use in a flexible, patient-centric approach in blepharospasm and CD, with injection intervals starting from 6 weeks. The efficacy, tolerability and safety of this regime were excellent. There is a need to optimise and individualise the treatment using the three available formulations of BoNT- A, as well as to define parameters for switching between the formulations.

AB - Botulinum toxin A (BoNT-A) has become the first-line therapy in cervical dystonia (CD), blepharospasm and spasticity. However, the current guidelines for the clinical use of BoNT-A are based on data published more than 20 years ago and patient satisfaction with current treatment regimens is low. There is a striking difference between the injection intervals given in everyday clinical practice and the injection intervals preferred by patients. Recent data have indicated that shorter injection intervals may improve overall patient satisfaction since re-emergence of symptoms could be prevented. Three double-blind studies have demonstrated that incobotulinumtoxin A (incoBoNT-A) is suitable for use in a flexible, patient-centric approach in blepharospasm and CD, with injection intervals starting from 6 weeks. The efficacy, tolerability and safety of this regime were excellent. There is a need to optimise and individualise the treatment using the three available formulations of BoNT- A, as well as to define parameters for switching between the formulations.

KW - Blepharospasm

KW - Botulinum toxin

KW - Cervical dystonia

KW - Incobotulinum toxin A

KW - Spasticity

UR - http://www.scopus.com/inward/record.url?scp=84929618204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929618204&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84929618204

VL - 10

SP - 28

EP - 34

JO - European Neurological Review

JF - European Neurological Review

SN - 1758-3837

IS - 1

ER -